Keyvenb (Human Hepatitis B Immunoglobulin)

The product supplies high‑titer anti‑hepatitis B surface antigen (anti‑HBs) antibodies. These antibodies bind to circulating hepatitis B virus particles, neutralizing them and blocking attachment to liver cells. This provides immediate, short‑term protection while the patient’s own immune system develops a longer‑lasting response.

The dose of Keyvenb is determined by the prescribing clinician based on the specific indication, patient weight, age, and the degree of exposure risk. No fixed regimen is provided here; the prescriber sets the appropriate amount and infusion rate for each individual case.

Safety data for Keyvenb during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To order Keyvenb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling) and import documentation.

The primary alternative to Keyvenb is the hepatitis B vaccine, which induces active immunity through antigen exposure. Keyvenb provides immediate passive immunity via antibodies, useful for post‑exposure situations or newborns, whereas the vaccine requires weeks to develop protective antibodies. Both may be used together for optimal protection in high‑risk scenarios.

Keyvenb must be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Follow any additional handling instructions provided by the manufacturer to maintain product stability.

Keyvenb is administered by intravenous infusion. The infusion should be performed under medical supervision, using aseptic technique, and the rate is adjusted according to the patient’s tolerance and the prescribing information. Monitoring of vital signs during and after the infusion is recommended.

Serious risks include anaphylactic or severe allergic reactions, hypotension, renal dysfunction, thrombotic events, serum sickness, and hemolysis. Patients should be observed closely during infusion, and any signs of these reactions require immediate medical intervention.

Keyvenb should not be used in individuals with a known hypersensitivity to human immunoglobulin preparations, or in patients with IgA deficiency who have anti‑IgA antibodies. It is also contraindicated in patients who have experienced severe reactions to previous immunoglobulin therapy.